New nerve pain drug shows promise in Year-Long trial

NCT ID NCT05890053

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested the long-term safety and effectiveness of HSK16149, a drug for nerve pain, in 301 Chinese patients over 52 weeks. All participants had previously completed a shorter trial and tolerated the drug. Researchers tracked side effects and pain scores to see if the drug remains safe and helpful over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HSK16149
What this could lead to
If successful, this could provide a long-term treatment option for people with nerve pain.
What could go wrong
This is an extension study, so participants already tolerated the drug. However, long-term side effects are still being monitored, and results may not apply to non-Chinese populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL NEURALGIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Baotou Central Hospital

    Baotou, Neimenggu, China

  • Beijing Pinggu District Hospital

    Beijing, Beijing Municipality, China

  • Cangzhou People's Hospital

    Cangzhou, Hebei, China

  • Emergency General Hospital

    Beijing, Beijing Municipality, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Kaifeng Hospital of Traditional Chinese Medicine

    Kaifeng, Henan, China

  • Nanjing First People's Hospital

    Nanjing, Jiangsu, China

  • Nanyang First People's Hospital

    Nanyang, Henan, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, China

  • Taizhou First People's Hospital

    Taizhou, Zhejiang, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Xi'an Medical University

    Xi’an, Shanxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The Second People's Hospital of Yibin

    Yibin, Sichuan, China

  • The Third Hospital of Hebei Medical University

    Shijiangzhuang, Hebei, China

  • The Three Gorges Hospital Affiliated to Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Wuhan Central Hospital

    Wuhan, Hubei, China

  • Yuncheng Central Hospital

    Yuncheng, Shanxi, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.